Galapagos

Companies Galapagos

News Galapagos

• Galapagos acquires Cangenix, a structure-based drug discovery company

  Galapagos NV (GLPG) and Cangenix Ltd announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering.   Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 potential ea more

• Galapagos discovers novel class of antibiotics

  Galapagos NV announced that it has discovered an entirely new class of antibiotics.  The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains.Bacterial infections that have bec more

• Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders

  Galapagos NV announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.  Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinica more

Publications Galapagos

• Invasive species: The 18-km2 rat trap

  Invasive species: The 18-km2 rat trap Nature 497, 7449 (2013). http://www.nature.com/doifinder/10.1038/497306a Author: Henry Nicholls Ecuador has successfully eradicated invasive pigs and goats from most of the Galapagos archipelago. more

• The legacy of Lonesome George

  The legacy of Lonesome George Nature 487, 7407 (2012). http://www.nature.com/doifinder/10.1038/487279a Author: Henry Nicholls Tortoise’s death spurs Galapagos conservation efforts. more

• Ecological and evolutionary determinants for the adaptive radiation of the Madagascan vangas [Evolution]

  Adaptive radiation is the rapid diversification of a single lineage into many species that inhabit a variety of environments or use a variety of resources and differ in traits required to exploit these. Why some lineages undergo adaptive radiation is not well-understood, but filling unoccupied ecolo more

Market studies Galapagos

• Chiesi Farmaceutici SpA - Strategic SWOT Analysis Review

  Chiesi Farmaceutici SpA is a European pharmaceutical company, engaged in research, development and commercialization of ethical therapeutic products. The company is also engaged in developing and bringing added value innovative pharmaceutical solutions. It operates in Spain, Brazil, the US, the UK, more

• Galapagos NV (GLPGA) - Financial and Strategic SWOT Analysis Review

  Galapagos NV (Galapagos) is a publicly held research focused biopharmaceutical company. It is engaged in discovery and development of disease modifying drugs. The company develops GLPG0259 that targets protein kinase MAPKAPK5, as its leading drug candidate for the under initial stages of clinical tr more

• TiGenix NV (TIG) - Financial and Strategic SWOT Analysis Review

  TiGenix NV (TiGenix) is a publicly held Belgium-based biomedical company. TiGenix is engaged in the development of innovative local treatments for damaged cartilage and osteoarthritis joints. It markets its flag ship product, ChondroCelect, as a regenerative medicine to treat cartilage defects. TiGe more

Websites Galapagos